FITC Anti-CD11a antibody [MEM-25]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CD11a also known as ITGAL and LFA-1 alpha chain or integrin alpha L is a protein that functions as an important component of the immune system. It has a molecular mass of approximately 180 kDa. CD11a is expressed predominantly in leukocytes enabling these immune cells to adhere and interact with other cells. This adhesive property is especially critical in the trafficking of leukocytes to sites of inflammation and infection. CD11a pairs with CD18 to form the leukocyte function-associated antigen-1 (LFA-1) complex which plays a significant role in cell signaling and immune responses.

Biological function summary

This protein enables leukocyte adhesion and transendothelial migration which are essential for the immune surveillance process. CD11a is a part of the integrin family known for regulating cell adhesion and interactions with the extracellular matrix. By forming a heterodimer with CD18 it mediates tight adhesion between immune cells and endothelial cells. This interaction aids in the immune response by enhancing the activation and movement of T cells and other leukocytes through the vascular endothelium into tissues.

Pathways

The protein participates in the immune cell trafficking pathway and the integrin signaling pathway. In these pathways CD11a contributes to the modulation of immune responses and cell movement. The interaction of CD11a with intercellular adhesion molecule 1 (ICAM-1) and other proteins within these pathways emphasizes its role in the firm adhesion of leukocytes during inflammation and infection ultimately facilitating leukocyte extravasation and tissue infiltration.

Associated diseases and disorders

CD11a is highly relevant to autoimmune diseases such as psoriasis and multiple sclerosis. For instance in psoriasis the overactive immune response involves overexpression of integrins including CD11a leading to inflammation. The protein Efalizumab a monoclonal antibody against CD11a has been used in the treatment of psoriasis to reduce leukocyte adhesion and activation. Such relationships highlight CD11a's critical role in both normal immune function and pathological conditions.